Sugi Predict

Sugi Predict / Compounds / SCHEMBL167872

SCHEMBL167872

SCHEMBL167872

COc1cc2nccc(Oc3ccc(NC(=O)c4nn(C)c5ccccc45)cc3F)c2cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 15/20 0.72
▸ AXL P30530 12/20 0.72
▸ AURKA O14965 1/20 0.62
▸ JAK2 O60674 1/20 0.62
▸ RPS6KA5 O75582 1/20 0.62
▸ ABL1 P00519 1/20 0.62
▸ INSR P06213 1/20 0.62
▸ LCK P06239 1/20 0.62
▸ RET P07949 1/20 0.62
▸ IGF1R P08069 1/20 0.62
▸ KIT P10721 1/20 0.62
▸ PIM1 P11309 1/20 0.62
▸ FGFR1 P11362 1/20 0.62
▸ SRC P12931 1/20 0.62
▸ PRKACA P17612 1/20 0.62
▸ RPS6KB1 P23443 1/20 0.62
▸ JAK1 P23458 1/20 0.62
▸ MAPK3 P27361 1/20 0.62
▸ AKT1 P31749 1/20 0.62
▸ AKT2 P31751 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL697701 0.96 MET (0.68) METAXLAURKAJAK2RPS6KA5
SCHEMBL16089972 0.84 MET (1.00) METAXL
SCHEMBL16089977 0.83 MET (1.00) METAXL
SCHEMBL166768 0.82 AXL (0.69) METAXL
SCHEMBL19579349 0.82 MET (0.89) METAXL
SCHEMBL167638 0.82 AXL (0.69) METAXLAURKAJAK2RPS6KA5
SCHEMBL16089962 0.81 MET (0.83) METAXL
SCHEMBL30716505 0.81 MET (0.70) METAXLAURKAJAK2RPS6KA5
SCHEMBL167947 0.81 AXL (0.67) METAXLAURKAJAK2RPS6KA5
SCHEMBL18549147 0.81 MET (0.87) METAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 — — US claimed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 — — EP claimed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 — — US claimed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 — — EP claimed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 — — WO claimed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 — — EP claimed
US-20200392110-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-12-17 — — US disclosed
EP-3415501-B9 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-12-02 — — EP disclosed
US-10676462-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 — — US disclosed
US-10501442-B2 Quinoline derivative ONO PHARMACEUTICALS CO., LTD. (JP) 2019-12-10 — — US disclosed
US-20190135785-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-09 — — US disclosed
US-10208022-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 — — US disclosed
US-9994549-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-12 — — US disclosed
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 — — US disclosed
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 — — US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 — — EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 — — US disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 — — US disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 — — US disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392110-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MET 97/4885AXL 2/4885AURKA 322/4885
US-10501442-B2 Quinoline derivative FLT3, AXL, ERBB2 MET 97/4885AXL 2/4885AURKA 322/4885
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 MET 8/4885AXL 1/4885AURKA 203/4885
US-10208022-B2 Quinoline derivative FLT3, AXL, ERBB2 MET 97/4885AXL 2/4885AURKA 322/4885
US-10676462-B2 Quinoline derivative FLT3, AXL, ERBB2 MET 97/4885AXL 2/4885AURKA 322/4885
US-20190135785-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 MET 97/4885AXL 2/4885AURKA 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.